```
=> file caplus
FILE 'CAPLUS' ENTERED AT 16:19:47 ON 29 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Sep 2010  VOL 153 ISS 14
FILE LAST UPDATED: 28 Sep 2010  (20100928/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d que
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3             4 SEA FILE=REGISTRY SSS FUL L1
L4             1 SEA FILE=CAPLUS L3


=> d l4 ibib abs hitstr
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:523445 CAPLUS
DOCUMENT NUMBER: 143:59979
TITLE: Preparation of (indol-1-yl), (indazol-1-yl), and (benzimidazol-1-yl)acetic acids useful for the treatment of respiratory disorders mediated by prostaglandin D2 acting at the CRTh2 receptor
INVENTOR(S): Bonnert, Roger Victor; Mohammed, Rukhsana Tasneem; Teague, Simon
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054232	A1	20050616	WO 2004-GB4937	20041124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1699781	A1	20060913	EP 2004-798644	20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1906189	A	20070131	CN 2004-80040941	20041124
JP 2007512299	T	20070517	JP 2006-540603	20041124
IN 2006DN03671	A	20070713	IN 2006-DN3671	20060626
US 20080027092	A1	20080131	US 2007-580576	20070525
PRIORITY APPLN. INFO.:			SE 2003-3180 A	20031126
			WO 2004-GB4937 W	20041124

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:59979; MARPAT 143:59979
GI



I



II

AB Title compds. I [wherein each A, B, D, E = indepedently CH and derivs., N; Y = C-R2, N, CO; Z = O, S, a bond, or alkylene; R2 = (un)substituted alkyl; R3 = (un)substituted hetero/aryl; X = N, C, CH] were prepared as CRTh2 receptor ligands for treating respiratory diseases. For example, II was prepared in 3 steps by reacting 5-iodoindazole with bis(4-chlorophenyl)disulfide in the presence of KOBu-t, followed by N-alkylation of indazole with Et bromoacetate and saponification of the ester (no data). I had IC50 values < 10 μM in a ligand binding assay using HEK cell membranes containing CRTh2 receptor. Thus, I and their formulations are useful for treating respiratory diseases, such as asthma and rhinitis, mediated by prostaglandin D2 acting at the CRTh2 receptor.

IT 854018-51-2P, 5-Methyl-3-(4-quinolinyl)-1H-indazole-1-acetic acid 854018-56-7P, 5-Cyano-3-(4-quinolinyl)-1H-indazole-1-acetic acid 854018-61-4P, 2-[3-(6-Fluoro-4-quinolinyl)-4-(trifluoromethyl)-1H-indazol-1-yl]acetic acid 854018-66-9P, 4-Iodo-3-(4-quinolinyl)-1H-indazole-1-acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indolyl, indazolyl, and benzimidazolylacetic acids as CRTh2 receptor ligands for treating respiratory diseases)

RN 854018-51-2 CAPLUS

CN 1H-Indazole-1-acetic acid, 5-methyl-3-(4-quinolinyl)- (CA INDEX NAME)



RN 854018-56-7 CAPLUS
CN 1H-Indazole-1-acetic acid, 5-cyano-3-(4-quinolinyl)- (CA INDEX NAME)



RN 854018-61-4 CAPLUS
CN 1H-Indazole-1-acetic acid, 3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-
(CA INDEX NAME)



RN 854018-66-9 CAPLUS
CN 1H-Indazole-1-acetic acid, 4-iodo-3-(4-quinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file reg
FILE 'REGISTRY' ENTERED AT 16:33:14 ON 29 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2010 HIGHEST RN 1243477-20-4
DICTIONARY FILE UPDATES: 28 SEP 2010 HIGHEST RN 1243477-20-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.
L2 0 SEA FILE=REGISTRY SSS FUL L1

=>